Shots:
- The EC has approved a higher maintenance dose of Wegovy (7.2mg semaglutide; QW) for chronic weight management in adults with obesity across 27 EU countries
- Assessed in STEP UP trial (1,407 adults without diabetes) & STEP UP T2D (512 adults with obesity & T2D) trial, Wegovy 7.2mg achieved 21% mean weight loss vs ~2% (PBO) in pts without diabetes, with 1/3 pts losing ≥25% & 84% of weight loss from fat mass while preserving muscle
- Novo has also applied for EU approval of a 7.2mg single-dose pen for Wegovy, which could launch later this year if cleared; the 7.2mg dose is also under review by the US FDA & other global authorities
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports P-III (REIMAGINE 2) Trial Data on CagriSema for Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
